Illumina, Inc. $ILMN Stake Lessened by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 43.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 165,811 shares of the life sciences company’s stock after selling 129,900 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al owned about 0.11% of Illumina worth $45,379,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Illumina during the 2nd quarter valued at $3,374,423,000. Plato Investment Management Ltd acquired a new stake in shares of Illumina in the second quarter valued at $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Illumina in the second quarter valued at $30,501,000. Edmond DE Rothschild Holding S.A. bought a new position in Illumina during the second quarter valued at about $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new position in Illumina during the second quarter valued at about $6,711,000. Institutional investors own 89.42% of the company’s stock.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Insider Activity

In other Illumina news, Director Keith A. Meister sold 119,501 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the completion of the transaction, the director directly owned 770,350 shares in the company, valued at $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 2,061,235 shares of company stock worth $436,356,102. Corporate insiders own 2.90% of the company’s stock.

Illumina Stock Performance

ILMN opened at $235.99 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The firm has a market cap of $35.63 billion, a PE ratio of 40.62, a P/E/G ratio of 4.11 and a beta of 1.41. The business has a fifty day simple moving average of $249.30 and a 200-day simple moving average of $176.18. Illumina, Inc. has a fifty-two week low of $106.12 and a fifty-two week high of $309.35.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a return on equity of 29.41% and a net margin of 19.72%. Illumina’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.34 earnings per share. As a group, equities analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analyst Ratings Changes

ILMN has been the topic of several research reports. Piper Sandler boosted their price target on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Argus raised their price objective on shares of Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Illumina in a research report on Monday, August 31st. JPMorgan Chase & Co. lowered their price objective on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $135.00 to $260.00 in a report on Wednesday, September 9th. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $238.53.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.